{
    "2021-07-16": [
        [
            {
                "time": "2023-10-18",
                "original_text": "AbbVie, Lilly Atopic Dermatitis Treatments Hit With Further Delays With FDA",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Lilly",
                        "Atopic Dermatitis",
                        "Delays",
                        "FDA"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-18",
                "original_text": "7 Best Dividend Stocks to Buy to Juice Your Portfolio Yield",
                "features": {
                    "keywords": [
                        "Dividend Stocks",
                        "Portfolio Yield"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "finance",
                        "investing"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-18",
                "original_text": "AbbVie, Lilly face fresh delays in FDA approval for expanded use of arthritis drugs",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Lilly",
                        "FDA",
                        "Arthritis Drugs",
                        "Delays"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-18",
                "original_text": "AbbVie Provides Update Regarding RINVOQÂ® (upadacitinib) for the Treatment of Moderate to Severe Atopic Dermatitis in the U.S.",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "RINVOQ",
                        "Upadacitinib",
                        "Atopic Dermatitis",
                        "U.S."
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}